Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma

A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00598104

Enrollment

Registered

2008-01-18

Start date

2008-01-31

Completion date

Unknown

Last updated

2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, interleukin-13

Brief summary

This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma

Interventions

DRUGQAX576

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* History of asthma attacks * Taking inhaled corticosteroids * Non-smoking

Exclusion criteria

* Women of child-bearing potential * History of respiratory disease other than asthma * History of severe allergy to food or drugs * Previous use of monoclonal antibodies * Very low or high body weight Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
- Forced expiratory volume in 1 second (FEV1)at baseline and until study completion - Levels of eosinophils in sputum	Throughout the study

Secondary

Measure	Time frame
- Three doses of QAX576 on time to treatment failure, plasma IL-13 levels and immunogenicity in asthmatics - Sputum biomarkers	Throughout the study

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026